GSK's Jemperli Endometrial Cancer Treatment Gets Full FDA Approval
February 10 2023 - 2:53AM
Dow Jones News
By Joe Hoppe
GSK PLC said Friday that the U.S. Food and Drug Administration
has given full approval for its Jemperli endometrial cancer
treatment.
The pharmaceutical giant said approval was based on long-term
outcomes from the Garnet Phase 1 trial, which showed an overall
response rate of 45.4%.
Jemperli has been approved for the treatment of adult patients
with mismatch repair-deficient recurrent or advanced endometrial
cancer. In April 2021, the treatment received accelerated
approval.
Jemperli was discovered by AnaptysBio Inc. and licensed to
Tesaro Inc., now a part of GSK, under a collaboration and exclusive
license agreement signed in March 2014.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
February 10, 2023 02:38 ET (07:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
